5mg vial
Retatrutide (LY-3437943) is a novel single-molecule triple receptor agonist developed by Eli Lilly, currently in Phase 3 trials. Unlike semaglutide (GLP-1) or tirzepatide (GLP-1/GIP), retatrutide also activates the glucagon receptor - adding hepatic fat oxidation, thermogenesis and energy-expenditure mechanisms absent from prior-generation agents.
Checking availability…
Balanced agonism of GIP (incretin effect and adipocyte lipid metabolism), GLP-1 (satiety, insulin secretion, delayed gastric emptying) and glucagon (hepatic fat oxidation, thermogenesis, basal metabolic rate). The glucagon arm is uniquely responsible for elevated energy expenditure vs GLP-1/GIP duals.
Phase 2/3 escalation: 2mg weekly (weeks 1–4) → 4mg (weeks 5–8) → 8mg (weeks 9–12) → maintenance at 8mg or 12mg weekly based on tolerability. Subcutaneous (abdomen, thigh or upper arm). Not FDA-approved - research use only.
approx. 144 hours (approx. 6 days), enabling once-weekly dosing.
Reconstitute 5–10mg vials with 1–2mL bacteriostatic water for a 4–8mg/mL working concentration. Swirl gently - do not agitate vigorously.
Lyophilised: 2–8°C (stable 24–36 months); avoid freeze-thaw cycling. Reconstituted: 2–8°C, do not freeze, use within 28 days.